Abstract
Advanced metastatic breast cancer is commonly considered as an incurable disease. In spite of the high rate of objective remissions achieved with the most recent polychemotherapy regimens or hormonal manipulations, the duration of response is limited, the disease progresses and, after a median interval of 24–36 months from the appearance of clinically detectable metastases, the patients inexorably die from cancer. Currently, there are two broad categories of treatment for metastatic breast cancer: cytotoxic chemotherapy and hormonal treatment. Women who are known to have a hormone-dependent tumor usually receive hormonal therapies, as these are better tolerated than chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group (2002). Anastrozole alone or in combination with tamoxifen vs. tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 359, 2131–2139.
Buzdar A.U. (2001). A summary of second-line randomised studies of aromatase inhibitors. J Steroid Biochem Mol Biol, 79, 10–114.
Day R., Ganz P.A. and Constantino J.P. (1999). Health-related quality of life and tamoxifen in breast cancer prevention. A report from the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Clin Oncol, 17, 2659–2669.
Demissie S., Silliman R.A. and Lash T.L. (2001). Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol, 19, 322–328.
Dombernowsky P. (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer. Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol, 16, 453–461.
Early Breast Cancer Trialists Collaborative Group (1992). Systemic treatment of early
breast cancer by hormonal, cytotoxic or immune therapy. 133 randomised trials involving 31,000 recurrencies and 24,000 deaths among 75,000 women. Lancet, 339, 1–15
Eiermann W., Paepke S. and Appfelstaedt J. (2001). Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol, 12, 1527–1532.
Elisaf M.S., Bairaktari E.T. and Niolaides C. (2001). Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer, 37, 1510–1513.
Ellis M.J., Coop A. and Singh B. (2001). Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or Erbb-z-positive, estrogen receptor-positive primary: evidence from a phase III randomized trial. J Clin Oncol, 19, 3808–3816.
Fallowfield L., Fleissig A. and Edwards R. (2001). Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol, 19, 1885–1892.
Ganz P.A., Day R. and Ware J.E. Jr (2001). Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project prevention (Pvi) randomized study. J Natl Cancer Inst, 93, 1615–1623.
Gershanovich M. (1998). Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol, 9, 639–645.
Goss P.E. and Strasser K. (2001). Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol, 19, 881–894.
Gruber C.J., Tschugguel W., Schneeberger C. and Huber J.C. (2002). Production and actions of estrogens. N Rugl J Med, 346, 340–352.
Hamilton A. and Piccart M. (1999). The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol, 10, 377–384.
Lipton A., Ali S.M. and Keitzel K. (2002). Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol, 20, 1467–1472.
Merlano M.C. (2002). Maintenace therapy with letrozole after first-line chemotherapy in advanced breast cancer: the MANTLE trial. 38th ASCO, Orlando (FL), May 18–21, Abstract 1996, 46b.
Mortimer J.E., Boucher L. and Knapp D.L. (1999). Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol, 17, 1488–1492.
Mouridsen H., Gershanovic M. and Sun Y. (2001). Superior efficacy of letrozole vs. tamoxifen as first-line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol, 19, 2596–2606.
Robertson J.P.R., Willsher P.C., Cheung K.L. and Blarney R.W. (1997). The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer, 33, 1774–1779.
Rose C. (2002). Letrozole (Femara) vs. anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer. 38th ASCO, Orlando (FL), May 18–21, Abstract 131, 34a.
Thomas R. (2002). Empowering patients to make informed treatment decisions based on tolerability, quality of life patient preference. A comparison of letrozole and anastrozole in a multicentre randomised, single-blind cross over study. EBCC, Barcelona, Spain, March 2002, 200, Abstract 171.
Thurlimann J.B., Hsu Schmitz S.P. and Castiglione-Gersch M. (1999). Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? J Clin Oncol, 17, 1672–1679.
Yamauchi H., Stearns V. and Hayes D.P.(2001): When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol, 19, 2234–2356.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Italia
About this paper
Cite this paper
Pronzato, P., Tognoni, A. (2003). Letrozole in the Treatment of Advanced Breast Cancer. In: Müller, E.E. (eds) Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance. Springer, Milano. https://doi.org/10.1007/978-88-470-2085-6_17
Download citation
DOI: https://doi.org/10.1007/978-88-470-2085-6_17
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2170-9
Online ISBN: 978-88-470-2085-6
eBook Packages: Springer Book Archive